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Objectives: The endopeptidase matrix metalloproteinase-9 (MMP-9) is implicated in atherosclerotic
plaque rupture. We investigate prospective associations between MMP-9 and MI or stroke in an older
general population cohort, accounting for established and novel cardiovascular risk factors.
Methods: Baseline serum MMP-9 was measured in incident MI (n=368) and stroke (n=299) cases and
two controls per case, ‘nested’ in prospective studies of 4252 men and 4286 women aged 60–79 years,
sampled from General Practices in Britain in 1998–2000, with 7-year follow-up for fatal and non-fatal
MI and stroke.
Results: Geometric mean MMP-9 was 528ng/mL (IQR 397, 743) in MI cases compared to 501ng/mL (IQR
370, 743) in controls, p=0.10. Participants in the top compared to bottom third of MMP-9 levels had an
age-adjusted odds ratio for MI of 1.53 (95% CI 1.09, 2.13), which attenuated to 1.18 (95% CI 0.81, 1.70)MP-9
rospective
ohort
after adjustment for established and novel cardiovascular risk factors. There was weak evidence that OR
differed according to pre-existing CVD; the OR for MI in 187 participants with pre-existing CVDwas 2.20
(1.04, 4.64) and 1.24 (0.84, 1.82) in 715 participants without (LR test for interaction p=0.06). Geometric
meanMMP-9 levels were higher in stroke cases than controls; 522ng/mL (IQR 363, 673) vs 487 (IQR 393,
704), p=0.045; however adjustments similarly attenuated the associations.
Conclusions: While serum MMP-9 is univariately associated with risk of MI and stroke, it is not a strong
for eiindependent risk marker
. Introduction
Experimental evidence suggests thatmatrixmetalloproteinase-
(MMP-9) may play a causal role in new-onset cardiovascular
isease (CVD).MMP-9may contribute toweakening and rupture of
therosclerotic plaques.MMP-9 (also knownas gelatinaseB, 92kDa
ollagenase) is one of a family of endopeptidase enzymes involved
n the degradation and re-organisation of the extra-cellular matrix
hich is involved in vascular remodeling; inappropriate or absent
Abbreviations: MMP-9, matrix metalloproteinase-9; MI, myocardial infarction;
VD, cardiovascular disease; CHD, coronary heart disease; OR, odds ratio; IQR, inter-
uartile range; CI, conﬁdence interval; CRP, C-reactive protein; IL-6, interleukin-6;
MI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
-PA, tissue plasminogen activator; LR, likelihood ratio.
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E-mail address: b.jefferis@pcps.ucl.ac.uk (B.J. Jefferis).
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remodeling can promote atherosclerosis or restenosis [1]. MMPs
are expressed in cells includingmacrophages, endothelial cells and
vascular smoothmuscle cells and have been identiﬁed in the shoul-
der area of human plaques where MMPs may promote the ﬁbrous
cap to weaken, destabilizing the plaque [2].
Despite the experimental evidence, few epidemiologic studies
have investigated associations between MMP-9 and myocardial
infarction (MI) or stroke onset. Most have exclusively studied
patients with existing CVD [3–6]. Among these, the Atherogene
study reported elevated risk of CVDmortality (n=97 deaths)which
was completely attenuated by adjustment for classical risk factors
and inﬂammatory markers [3]. Yet smaller studies did not report
signiﬁcant associations with CHD risk (n<65 cases), although type
Open access under CC BY-NC-ND license.2 error due to the small sample size may account for this [4,5].
Another study of patients with carotid stenosis reported elevated
risk of onset of ipsilateral stroke or cardiovascular death (n=53
cases) but did not account for inﬂammatory markers [6]. Little
evidence exists aboutMMP-9 and CVDonset frompopulation stud-
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es; the only prospective study of healthy individuals is a study
ased on a different subset of the cohort of men investigated here
hen they were middle aged, and reported modest positive asso-
iations between serumMMP-9 levels andMI onset (n=465 cases),
ut associationsweremediated by factors associatedwithMMP-9;
otably cigarette smoking and inﬂammatory markers CRP and IL-6
7]. Evidence from genetic studies about the role of MMP-9 in CVD
s mixed [3,8–11].
We have therefore examined associations between MMP-9 and
I and stroke in two prospective population-based studies of older
en andwomen, taking account of a range of established andnovel
ardiovascular risk factors, particularly inﬂammatory markers CRP
nd IL-6. We investigate whether the associations differ between
articipants with evidence of pre-existing CVD (MI and stroke) and
he healthy population, as previous studies have not addressed this
uestion. We also investigate whether associations differ between
mokers and non-smokers given the higher burden of atheroscle-
osis in non-smokers and previous ﬁndings that MMP-9 is higher
n smokers [3,7].
. Methods
In 1998–2000, 4252 men from a single General Practice in each
f 24 British towns who were already participating in a prospec-
ive study of CVD ongoing since 1978–1980, attended for follow-up
easurements at the age of 60–79 years (response rate 77%) [12].
n 1999–2001, a parallel study of 4286 women of the same age
nd in the same Practices was established, omitting two study
owns (Dewsbury and Maidstone) and adding one other (Bristol)
13]. Near identical study protocols were used. In both studies,
urses administered questionnaires, made physicalmeasurements
weight, height and seated blood pressure), recorded an ECG and
ollected fasting venous blood samples, from which serum was
tored at ≤−70 ◦C for subsequent analysis of lipids, hemostatic
nd inﬂammatory markers as described elsewhere [12–15]. MMP-
(ng/mL) was measured in 2007 using a commercially available
andwich ELISA (R&D Systems, Oxon, UK) (intra-assay CV 4.4%,
nter-assay CV 10.4%) by researchers blinded to case–control sta-
us of samples. In two study towns, MMP-9 was measured in
38 men in 1996 and again in 2000, to enable intra-individual
omparisons of values over time [16]. Participants completed
etailed questionnaires. Pre-existing CVD was deﬁned from val-
dated reports from General Practitioner, or self-report of MI or
troke at any questionnaire between 1978–1980 and 1998–2000
n men and in the baseline questionnaire (1999/2000) in women
12]. Data on cigarette smoking, alcohol consumption, physical
ctivity, own longest-held occupation (or husband’s occupation for
on-married women, coded using the Registrar General’s classiﬁ-
ation) were self-reported. Region of residence was recorded for
omen in 1998–2000 and for men at the start of their follow-up in
978–1980. Participants were followed-up for 6.25–8.5 years for
ortality and cardiovascular morbidity, with a follow up loss of
2%. Fatal cases were ascertained through National Health Service
entral Registers from a death certiﬁcate: ICD-9 codes 410–414
or MI and ICD-9 codes 430–438 for stroke, indicating deaths with
erebrovascular disease as the underlying cause. Non-fatal MI or
troke was diagnosed using World Health Organisation diagnostic
riteria based on validated reports fromGeneral Practitioners, sup-
lemented by regular reviews of General Practice records [12,17].
articipants provided written informed consent to the investiga-
ionandethical approvalwasprovidedbyall relevant local research
thics committees.
We established a nested case–control study based on all 390
I cases occurring between examination date (1998–2000) and
une 2006 inmen and between examination date (1999–2001) andsis 208 (2010) 557–563
September 2007 in women. 780 controls “frequency matched” to
cases on town of residence, gender and age in 5-year bands were
randomly selected from among subjects who survived to the end
of the study free from incident CVD. Similar methods were used to
establish a separate nested case–control study based on 324 cases
of stroke and 648 (different) frequency matched controls.
2.1. Statistical analyses
Highly skewed variables were transformed using natural loga-
rithms and baseline (age 60–79 years) characteristics of theMI case
and control populations were calculated (mean and standard devi-
ation, median and IQR for skewed variables, or n (%) for categorical
variables). Continuous variables were adjusted for gender, region
of residence and age. Tertiles of MMP-9 were deﬁned separately in
the MI and stroke control samples. Associations between tertiles
of MMP-9 and covariables were examined using one-way ANOVA.
Unmatched logistic regressionanalyseswereused toexamineasso-
ciations between tertiles of MMP-9 and MI. Models were adjusted
for cardiovascular risk factors selected a priori: (i) gender, age and
region of residence; (ii) smoking status (current, ex, never); (iii)
history of diabetes, or CHD, social class (manual or non-manual),
alcohol use (1–2 drinks/day or other) physical activity (more or less
than 3h ofmoderate/vigorous activity perweek), systolic and dias-
tolicbloodpressure (SBPandDBP), bodymass index (BMI), total and
HDL cholesterol as continuous variables; (iv) CRP and IL-6. Linear
regressionmodels of continuousMMP-9, log transformed to base 2
were used to assess the effect of a doubling of MMP-9 level on MI.
Differences in theMMP-9-CVD associationswere tested using like-
lihood ratio (LR) tests for interactions by gender, age, pre-existing
CHDandcurrent smokingstatus.With302MIcasesavailable for the
multivariate analyses, we had 80% power to detect a relative risk of
1.66 in the top tertiles of MMP-9 compared to the bottom tertiles,
at the 5% statistical signiﬁcance level, assuming two controls per
case. For the 237 stroke cases, the equivalent relative risk was 1.79.
Rosner’s method was used to calculate regression dilution ratios
on a subset of men with repeated MMP-9 measurements, using a
linear regression model of the repeat measurement predicted by
the ﬁrst measurement [18].
3. Results
3.1. MI
Baseline characteristics of MI cases and controls are shown in
Table 1. MMP-9 levels were available for 368 of 390 MI cases (270
men and 98 women aged on average 70.8 years) and for 713 of
780 controls. Cases had higher prevalences of pre-existing CVD (MI
or stroke) and diabetes than controls, were more likely to smoke
cigarettes and less likely to be physically active or light drinkers (all
p<0.02) and had higher mean SBP, total cholesterol, triglycerides,
insulin, glucose, CRP, IL-6, lowerHDL cholesterol and forced expira-
tory volume (FEV1) and similar SEP, BMI and DBP. Geometric mean
serum MMP-9 was 5% higher (95% CI 4%, 6%) in the MI cases than
the controls; 527ng/mL (IQR397, 743) compared to501ng/mL (IQR
3670, 743), p (no difference) =0.096.
3.2. Stroke
MMP-9 data were available for 304 of 324 stroke cases (194
men and 110 women, mean age 71.4 years) and 596 of 648 con-
trols. Characteristics of stroke cases and controls are shown in
Table 1. Cases had higher prevalence of pre-existing CVD and cur-
rent smokers than controls (both p<0.003), but similar SEP, alcohol
use, physical activity and prevalence of pre-existing diabetes. Cases
had higher mean blood pressure, total cholesterol, IL-6 and white
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Table 1
Baseline characteristics (age 60–79) of the MI cases and controls and stroke cases and controls: mean (SD) or n (%)a.
MI cases
(n=368)
MI controls
(n=713)
Difference
(p-value)
Stroke cases
(n=304)
Stroke controls
(n=596)
Difference
(p-value)
Demographic/questionnaire
Age (years) 70.83 (5.46) 70.80 (5.43) Matched 71.36 (5.32) 71.39 (5.26) Matched
Male, n (%) 270 (73.4) 516 (72.4) Matched 194 (63.2) 377 (63.3) Matched
Northern region of residence, n (%)b 156 (42.4) 298 (41.8) Matched 111 (36.5) 227 (38.1) Matched
Non-manual occupation, n (%)b 155 (44.5) 325 (47.8) 0.333 125 (46.6) 263 (47.2) 0.632
Prior evidence of CVD, n (%) 111 (30.2) 119 (16.7) <0.001 86 (28.3) 90 (15.1) <0.001
History of diabetes, n (%) 66 (17.9) 76 (10.7) 0.001 43 (14.1) 73 (12.3) 0.422
1–2 alcoholic drinks/day, n (%) 129 (38.2) 304 (46.2) 0.015 129 (38.2) 304 (46.2) 0.913
Current smoker, n (%) 77 (20.9) 94 (13.2) 0.002 53 (17.4) 58 (9.8) 0.002
Physical activity (inactive/occasional), n (%) 235 (66.4) 401 (58.8) 0.017 199 (71.7) 383 (66.8) 0.213
Physical measurements
Body mass index (kg/m2)c,d 27.06 (4.23) 27.02 (3.96) 0.934 27.06 (4.33) 27.06 (4.09) 0.828
Systolic blood pressure (mm/Hg)c,d,e 153.89 (27.29) 148.69 (24.03) 0.001 154.32 (24.96) 149.37 (24.42) 0.005
Diastolic blood pressure (mm/Hg)c,d,e 83.77 (12.09) 83.28 (11.50) 0.512 84.98 (12.61) 82.45 (11.29) 0.002
FEV1 (L/min)c,d, f 2.15 (0.55) 2.23 (0.60) 0.028 2.09 (0.57) 2.23 (0.53) <0.001
Lipids/metabolic markers
Total cholesterol (mmol/L)c 6.24 (1.23) 6.09 (1.07) 0.032 6.13 (1.21) 6.32 (1.17) 0.023
HDL cholesterol (mmol/L)c 1.32 (0.33) 1.42 (0.36) <0.001 1.43 (0.40) 1.43 (0.36) 0.924
Triglyceride (mmol/L)c,e ,g 1.80 (1.31, 2.41) 1.58 (1.13,2.09) <0.001 1.64 (1.11, 2.32) 1.69 (1.23, 2.29) 0.468
Inﬂammatory markers
MMP-9 (ng/mL)c,g 527 (397, 743) 501 (370, 743) 0.096 522 (363, 673) 487 (393, 704) 0.045
C-reactive protein (mg/L)c,g 2.39 (1.05, 5.39) 1.77 (0.89, 3.62) <0.001 2.12 (1.04, 4.35) 1.92 (0.91, 4.10) 0.173
IL-6 (pg/mL)c,e ,g 2.97 (1.92, 4.07) 2.43(1.61, 3.43) <0.001 2.83 (1.87, 4.14) 2.56 (1.65, 3.55) 0.021
a Case–control sample is maximum available.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c Adjusted for gender, age and region of residence (Scotland, North, Midlands and South).
d Adjusted for nurse number.
e Adjusted for time of day.
f Adjusted for height squared.
g Analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.
Table 2
Association between MMP-9 (tertiles) and cardiovascular risk factors in the MI control sample (n=713).
Low (10–410) n=239 Medium (411–599) n=237 High (600–4496) n=237 Trend p-valuea
Demographic/questionnaire
Age (years) 70.81 70.29 71.31 0.310
Male, n (%) 162 (67.8) 173 (73.0) 181 (73.4) 0.037
Northern region, n (%)b 90 (37.7) 114 (48.1) 94 (39.7) 0.653
Non-manual occupation, n (%)b 105 (46.5) 116 (51.3) 104 (45.4) 0.819
Evidence of CVD, n (%) 40 (16.7) 38 (16.0) 41 (17.3) 0.870
History of diabetes, n (%) 16 (6.7) 34 (14.4) 26 (11.0) 0.131
1–2 alcoholic drinks/day, n (%) 102 (47.0) 104 (47.9) 98 (43.8) 0.490
Current smoker, n (%) 17 (7.11) 27 (11.4) 50 (21.1) <0.001
Physical activity (inactive/occasional), n (%) 127 (54.7) 132 (57.9) 142 (64.0) 0.047
Physical measurements
Body mass index (kg/m2)c,d 26.81 26.99 27.26 0.222
Systolic blood pressure (mm/Hg)c,e ,d 149.59 147.37 149.03 0.801
Diastolic blood pressure (mm/Hg)c,e ,d 83.44 82.66 83.72 0.798
FEV1 (L/min)c,d, f 2.34 2.20 2.14 <0.001
Lipids/metabolic markers
Total cholesterol (mmol/L)c 6.13 6.09 6.05 0.411
HDL cholesterol (mmol/L)c 1.44 1.42 1.40 0.219
Triglyceride (mmol/L)c,e ,g 1.55 1.60 1.59 0.562
Inﬂammatory markers
C-reactive protein (mg/L)c,g 1.35 1.65 2.48 <0.001
IL-6 (pg/mL)c,e ,g 2.09 2.29 2.86 <0.001
a Sample (n=713) MI controls with MMP-9 value. Trend test adjusted for age, gender, region of residence.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c Adjusted for gender, age and region of residence (Scotland, North, Midlands and South).
d Adjusted for nurse number.
e Adjusted for time of day.
f Adjusted for height squared.
g Geometric mean, p-value from linear regression with ln (variable).
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Table 3
Odds ratio (95% CI) of MI in men and women with MMP-9 values in the higher tertiles compared to the lower tertile of the distribution (i) all participants; (ii) participants
without CVD; (iii) participants with pre-existing CVDa.
MMP-9 MI cases MI controls OR (95% CI) with adjustments
Tertiles n n Model 1 Model 2 Model 3 Model 4
All participants (n=902)
Range (ng/mL)
600–4496 130 209 1.53 (1.09, 2.13) 1.40 (0.99, 1.97) 1.36 (0.96, 1.94) 1.18 (0.81, 1.70)
411–599 87 192 1.06 (0.74, 1.51) 1.06 (0.74, 1.52) 1.01 (0.70, 1.46) 0.99 (0.68, 1.43)
10–410 85 199 1 1 1 1
Total 302 600 p=0.010 p=0.049 p=0.123 p=0.373
Continuous: doubling of (MMP-9)b 302 600 1.20 (0.97, 1.48) 1.13 (0.91, 1.40) 1.11 (0.89, 1.39) 1.01 (0.81, 1.28)
Participants without pre-existing CVD (n=715)
Range (ng/mL)
600–4496 83 176 1.24 (0.84, 1.82) 1.09 (0.71, 1.63) 1.01 (0.67, 1.54) 0.85 (0.55, 1.31)
411–599 64 158 1.06 (0.71, 1.60) 1.08 (0.73, 1.63) 1.04 (0.68, 1.60) 0.97 (0.63, 1.50)
10–410 65 176 1 1 1 1
Total 212 503 p=0.281 p=0.671 p=0.959 p=0.451
Continuous: doubling of (MMP-9)b 212 503 1.11 (0.87, 1.42) 1.03 (0.81, 1.32) 1.01 (0.78, 1.32) 0.89 (0.68, 1.17)
Participants with pre-existing CVD (n=187)
Range (ng/mL)
600–4496 47 33 2.20 (1.04, 4.64) 2.17 (1.00, 4.71) 2.39 (1.05, 5.44) 2.52 (1.08, 5.87)
411–599 23 34 1.07 (0.48, 2.38) 1.06 (0.47, 2.38) 1.09 (0.47, 2.55) 1.11 (0.47, 2.46)
10–410 20 30 1 1 1 1
Total 90 97 p=0.023 p=0.034 p=0.026 p=0.023
Continuous: doubling of (MMP-9)b 90 97 1.28 (0.79, 2.05) 1.23 (0.75, 2.01) 1.20 (0.72, 2.00) 1.21 (0.72, 2.04)
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tors (model 3), corrected for regression dilution using Rosner’sodel 1 = age, gender and region. Model 2 =model 1 + smoking. Model 3 =model 2
+ IL-6 +CRP.
a Complete case analysis sample. Tertiles based on control group. P-value for test
b OR of MI per 1 log2 increase in log 2(MMP-9) i.e. doubling of MMP-9.
lood cell count, but lower FEV1 and similar BMI, HDL, triglyceride,
nsulin, glucose, CRP and ﬁbrinogen to controls.MMP-9 levelswere
% (95% CI 5%, 9%) higher among the stroke cases than the controls;
22ng/mL (IQR 363, 673) compared to 487ng/mL (IQR 393, 704), p
no difference) =0.045.
.3. Baseline correlates of MMP-9
Table 2 summarises the associations betweenMMP-9 and other
arkers of CVD risk across thirds of the MI control population (the
arger control population). Associations in the stroke control pop-
lation were similar unless speciﬁcally noted. MMP-9 levels were
igher in men and in smokers, but did not vary with age, social
lass or other behavioural factors, BMI or BP. MMP-9 was inversely
ssociated with FEV1. Weak inverse associations with lipids did
ot reach conventional levels of statistical signiﬁcance in the MI
ontrol population, although did in the stroke control population
p<0.02 for total andHDL cholesterol).MMP-9was positively asso-
iated with CRP and IL-6. Correlations between log MMP-9 and
ovariates were all r<0.3 (e.g. r=0.27 for CRP and r=0.28 for IL-6,
< 0.001).
.4. Association of MMP-9 with risk of MI
The odds ratio (OR) for MI associated with the highest com-
ared to the lowest third of MMP-9 and adjusted for age, gender
nd region of residence (model 1) was 1.53 (95% CI 1.09, 2.13) with
linear trend across the tertiles (p=0.01) (Table 3). Adjustment for
igarette smoking (model 2) attenuated the OR to 1.40 (95% CI 0.99,
.97), p (trend) 0.049. Further adjustments for established risk fac-
ors and for IL-6 and CRP (models 3 and 4) completely attenuated
he OR and linear trend. A doubling of MMP-9 level adjusted for
ge, gender and region of residence (model 1) was associated with
n OR for MI 1.20 (95% CI 0.97, 1.48), which was further reduced by
djustments.hol, physical activity, history of diabetes, BMI, SBP, DBP, TC, HDL. Model 4 =model
end over tertiles.
Therewas no evidence that associations betweenMI and tertiles
of MMP-9 or log2 MMP-9 varied by age, gender, or cigarette smok-
ing status (LR tests p>0.12). The OR forMI for a doubling of MMP-9
was 1.10 (95% CI 0.86, 1.40) inmen and 1.54 (1.00, 2.37) in women.
There wasweak evidence that the associationmay differ according
to pre-existing CVD status, LR test p=0.06. In the 715 participants
without CVD, the OR for MI in the top compared to bottom third of
MMP-9 adjusted for age, gender and region was 1.24 (95% CI 0.84,
1.82), linear trend p=0.281 (Table 3). The equivalent OR for MI in
the 187 participants with pre-existing CVD was 2.20 (1.04, 4.64),
linear trend, p=0.02. The OR was little changed on full adjustment
(Table 3).
3.5. Association of MMP-9 with risk of stroke
No signiﬁcant associations between MMP-9 and stroke were
observed in multivariate regression models (Table 4) in sample
with or without pre-existing CVD and there was no evidence for
interaction between by pre-existing CVD (Table 4), gender, age or
cigarette smoking (LR tests all p>0.22).
3.6. Impact of adjustment for regression dilution ratio
A regression dilution ratio of 0.46 (95% CI 0.32, 0.60) was
calculated in a subset of 138 men with MMP-9 levels mea-
sured 4 years apart [16]. The OR of MI among men in the top
third of MMP-9 compared with the lowest third and adjustedmethod for univariate models with RDR of 0.46 is 1.95 (95%
CI 0.92, 4.22) in the full sample. The equivalent adjusted esti-
mate for the full stroke sample using the RDR of 0.46 is 1.41
(95% CI 0.58, 3.33), further estimates are presented in Web
Table 1.
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Table 4
Odds ratio (95%CI) of stroke inmen andwomenwithMMP-9 values in the highest compared to lowest tertile (i) all participants; (ii) participantswithout CVD; (iii) participants
with pre-existing CVDa.
MMP-9 Stroke cases Stroke controls OR (95% CI) with adjustments
Tertiles n n Model 1 Model 2 Model 3 Model 4
All participants (n=734)
Range (ng/mL)
604–2296 89 165 1.36 (0.92, 2.00) 1.29 (0.87, 1.91) 1.17 (0.78, 1.74) 1.09 (0.72, 1.67)
401–603 82 170 1.20 (0.81, 1.77) 1.17 (0.79, 1.74) 1.11 (0.74, 1.67) 1.08 (0.72, 1.63)
10–400 66 162 1 1 1 1
Total 237 497 p=0.122 p=0.204 p=0.462 p=0.683
Continuous: doubling of MMP-9b 237 497 1.24 (0.98, 1.56) 1.20 (0.95, 1.51) 1.14 (0.90, 1.45) 1.10 (0.85, 1.41)
Participants without pre-existing CVD (n=598)
Range (ng/mL)
604–2296 65 138 1.48 (0.95, 2.32) 1.42 (0.90, 2.23) 1.30 (0.81, 2.06) 1.22 (0.75, 1.99)
401–603 59 144 1.30 (0.83, 2.05) 1.28 (0.81, 2.01) 1.25 (0.79, 1.99) 1.22 (0.76, 1.95)
10–400 46 146 1 1 1 1
Total 170 497 p=0.087 p=0.136 p=0.283 p=0.441
Continuous: doubling of (MMP-9)b 170 497 1.32 (1.02, 1.72) 1.29 (0.99, 1.68) 1.24 (0.94, 1.63) 1.20 (0.90, 1.60)
Participants with pre-existing CVD (n=136)
Range (ng/mL)
604–2296 24 24 1.00 (0.42, 2.39) 1.01 (0.42, 2.42) 0.86 (0.33, 2.25) 0.77 (0.28, 2.14)
401–603 23 26 0.89 (0.36, 2.17) 0.89 (0.36, 2.21) 0.87 (0.31, 2.46) 0.83 (0.29, 2.14)
10–400 20 19 1 1 1 1
Total 67 69 p=0.973 p=0.959 p=0.765 p=0.625
Continuous: doubling of (MMP-9)b 67 69 0.92 (0.52, 1.62) 0.89 (0.50, 1.58) 0.78 (0.41, 1.49) 0.72 (0.37, 1.42)
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a Complete case analysis sample. Tertiles based on control group. p-value for test
b OR of MI per 1 log2 increase in log 2(MMP-9) i.e. doubling of MMP-9.
. Discussion
Serum MMP-9 levels were positively associated with MI and
troke onset over a 7-year period in older men and women,
ut the association was explained by established and novel
isk factors, in particular cigarette smoking, and the inﬂamma-
ory markers CRP and IL-6. In the subset with pre-existing CVD
he associations of MMP-9 with onset of MI were somewhat
tronger than in those without pre-existing CVD and robust to
djustments.
.1. Comparison with previous studies
In line with other studies, MMP-9 levels did not vary with age
3,7,19], but were associated with smoking [3,7,20] and inﬂam-
atory markers (including CRP, IL-6, ﬁbrinogen and white blood
ell count) [3,7], but not consistently with other health behaviours
3,7,19], lipids, bloodpressure or BMI [3,7,19]. Theﬁnding of amod-
st association between MMP-9 and MI which was attenuated by
isk factor adjustment agrees closely with an earlier study of the
en’s cohort at age 40-59 years [7]. The Atherogene study, fol-
owing patients with coronary stenosis over 4 years, reported an
levated HR for CVD (1.3 (95% CI 1.1, 1.6) per quartile increase of
MP-9 after adjusting for established risk factors. As in our study,
he association was completely attenuated after adjustment for
nﬂammatory markers [3]. The observed attenuation is line with
xpectation as MMP-9 production may be inﬂuenced by cardio-
ascular risk factors such as smoking, CRP and IL-6 (which are
ssociated with serum MMP-9 in our current and previous studies
7] and with plasmaMMP-9 in a cross sectional study [20]. Smaller
tudies have not reported signiﬁcant associations between MMP-
and CVD, although they may lack power [4,5]. Data from some
3,8,9] studies of the associations between polymorphisms associ-
ted with MMP-9 and CVD-related outcomes lend weight to the
otential for a causal association between MMP-9 and MI onset.lcohol, physical activity, history of diabetes, history of CHD, BMI, SBP, DBP, TC, HDL.
end over tertiles.
However, the lack of consistency of the genetic studies caution
against this interpretation [3,10,11]. Our ﬁnding that the associ-
ations between MMP-9 and MI or stroke did not vary by gender,
smoking status (or indeed age) extends the literature as previ-
ous studies have not investigated such differences.We found some
weak suggestive evidence of a stronger association betweenMMP-
9 and MI in participants with pre-existing CVD. Although previous
studies have not tested this, it ﬁts with evidence from patient pop-
ulations suggesting thatMMP-9 is associatedwith CVD-risk, whilst
the evidence from healthy population is weaker. MMP-9 may be a
weaker marker of CHD risk in healthy sub-groups because MMP-9
maybemore important in de-stabilizing establishedplaques rather
than having a directly atherogenic effect. Speculatively, increased
expressionofMMP-9 (anddecreasedexpressionof tissue inhibitors
of MMPs [TIMPS]) may be one way in which increased circulat-
ing inﬂammatory markers increase the risk of rupture in existing
plaques [1,2] so thatMMP-9 could be a biomarker of rupture-prone
plaques. Our results however suggest that MMP-9 is probably too
moderately associated with CVD to be clinically useful biomarker,
although it may remain a potential therapeutic target, particularly
in individuals with pre-existing disease.
In relation to stroke, a study of patients with carotid stenosis
reported a combined HR for ipsilateral stroke or cardiovascular
death of 1.9 (95% CI 1.1, 3.5) for MMP-9 above vs below median
adjusted for risk factors including smoking [6]. We found no evi-
dence thatMMP-9 is independently associatedwithonset of stroke,
in line with epidemiologic [7] and genetic data [11].
4.2. Strengths and weaknessesThis study adds to scant prior evidence about the relations of
MMP-9 to CVD onset in generally healthy populations and is the
ﬁrst population-based prospective study of MMP-9 and CVD to
investigate gender interactions. The study,whichhad sufﬁcient size
and statistical power to exclude a relative risk of 1.68 between top
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nd bottom thirds of the MMP-9 distribution, beneﬁts from val-
dated data about MI and stroke events and comprehensive data
n a range of established and novel cardiovascular risk factors.
ew other studies have prospective data on MMP-9 and subse-
uent risk of either MI [3,7], or stroke [6]. The present study has a
onger follow-up period and more events than previous studies in
atient populations. One earlier population-based study reported
imilar results over a longer follow-up; it was based on a different
ested case–control sample of men taken from the same cohort
hat provided the nested case–control data presented here, but
he men’s MMP-9 measures were from when they were 20 years
ounger, and the CVD cases occurred over an earlier period, so the
tudies have minimal overlap [7]. The results of stratiﬁed analyses
uggested that positive associations ofMMP-9withMImay be par-
icularly strong in subjectswith pre-existing CHD.Whilst our study
s large in comparison with previous studies, the wide conﬁdence
ntervals indicate that we cannot exclude a modest but potentially
mportant association. This study, like most others, is limited by
aving only a single measure of MMP-9. However, we estimated
he intra-individual variability in serum MMP-9 levels. Estimates
uggested lower stability of serumMMP-9 than several established
isk factors [16] and after correction for within-person variability,
he ORs for MI and stroke were less conservative and reached con-
entional statistical signiﬁcance. The nested case–control design
equired that controls survived to the end of the studywhich could
ntroduce somebias, however since observed adjusted associations
ere modest and not signiﬁcant, bias is unlikely to be problem-
tic. Response rates were reasonably high and it is not thought
hat attrition would affect our estimate of the association between
MP-9 andCVD, priorwork on themen’s cohort suggests that non-
ttenders did not differ substantially from attenders [21]. Finally,
erum samples were used in preference to plasma because the
MP-9 ELISA assaywas not recommended for plasma samples due
o interfering chelation of EDTA and citrate during the assay pro-
ess. Some researchers have suggested thatmeasurement of serum
MP-9 may be problematic for the interpretation of results, on
he basis that levels of MMP-9 are higher in serum than plasma
22] suggesting platelet and leucocyte degranulation during clot-
ing elevates levels. However, we like others [23] challenge the
ssertion that serum MMP-9 measurements are never physiolog-
cally useful. Serum or plasma levels of MMP-9 may not be truly
eﬂective of MMP-9 concentrations within cellular rupture-prone
laques, which is mechanistically potentially the most important
ite of action for MMP-9. However, considering circulating MMP-9
s a biomarker, serum levels of MMP-9 correlate with both plasma
MP-9 and with the zymographically measured level of “active
irculating” MMP-9 [23,24]. Additionally, in healthy populations,
evels of detection of MMP-9 in plasma are very low, e.g. only 20%
f participants free of CHD in Framingham studies had detectable
lasma MMP-9 [19]. This may diminish the statistical power in
ubsequent data analysis. The validity of the serum MMP-9 lev-
ls, which were measured using standard laboratory protocols, is
upported by the comparability of correlates of serumMMP-9, ﬁrst
ith CHD risk factors [7,10], particularly smoking, and second, the
oderate associationswith CHDoutcomes are consistentwith ear-
ier reports [7,10], ﬁnally, serum data are consistent with data on
lasmaMMP-9 [3]. Therefore, we see no reason to suppose that, as
biomarker, serum levels of MMP-9 in a large controlled study are
ny less relevant than plasma levels, despite differences in absolute
evels detected..3. Implications
MMP-9 was associated with modestly elevated risks of MI and
troke, in large part due to confounding, particularly by cigarette
moking and inﬂammation. The conﬁdence limits of the estimates
[
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exclude effects of large magnitude, although any increase in risk
of MI or stroke with increasing MMP-9 could still be modest, even
after full adjustment. Our estimates of measurement imprecision
suggest that associations between MMP-9 and CVD are conserva-
tively estimated. Appreciably larger prospective studies, excluding
prevalent disease and with full adjustments for confounding fac-
tors would be necessary to exclude effects of moderate magnitude.
Further large studies could also investigate whether MMP-9 may
be a better biomarker of risk among patients with a history of
CVD than without, as we found only weak suggestive evidence and
conﬁdence intervals were wide. Our study suggests that MMP-9
provides little additional information to previously established risk
factors and given inconsistency in ﬁndings about MMP-9 andMI, it
is unlikely to be useful in identifying high-risk individuals.
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